Filing Details

Accession Number:
0001012975-19-000254
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-04-01 17:35:14
Reporting Period:
2019-04-01
Accepted Time:
2019-04-01 17:35:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1357874 Precision Biosciences Inc DTIL () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1278411 S Corey Goodman C/O Venbio Partners, Llc
1700 Owens Street, Suite 595
San Francisco CA 94158
No No Yes No
1329161 J Robert Adelman C/O Venbio Partners, Llc
1700 Owens Street, Suite 595
San Francisco CA 94158
Yes No Yes No
1504130 Venbio Global Strategic Fund, L.p. C/O Venbio Partners, Llc
1700 Owens Street, Suite 595
San Francisco CA 94158
Yes No Yes No
1770834 Venbio Global Strategic Gp, L.p. C/O Venbio Partners, Llc
1700 Owens Street, Suite 595
San Francisco CA 94158
No No Yes No
1770835 Venbio Global Strategic Gp, Ltd. C/O Venbio Partners, Llc
1700 Owens Street, Suite 595
San Francisco CA 94158
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-04-01 50,000 $16.00 50,000 No 4 P Indirect See footnote
Common Stock Acquisiton 2019-04-01 3,747,623 $0.00 3,797,623 No 4 C Indirect See footnote
Common Stock Acquisiton 2019-04-01 467,518 $0.00 4,265,141 No 4 C Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2019-04-01 8,000,000 $0.00 3,747,623 $0.00
Common Stock Series B Preferred Stock Disposition 2019-04-01 998,004 $0.00 467,518 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering.
  2. venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.